DEA Final Order Creates Federal Pathway for Medical Marijuana

Federal cannabis law has never tracked cleanly with the illicit, and then state-legal markets that grew up around it. For decades, marijuana was listed on Schedule I under the Controlled Substances Act, while states built medical programs of their own. In 2018, the DEA took its first baby step regarding marijuana, placing certain FDA-approved cannabidiol products on Schedule V rather than treating them as Schedule I marijuana. Now, DEA’s April 23, 2026 final order on FDA-approved and state-licensed medical marijuana products places three sets of products and activities on Schedule III under 21 U.S.C. § 811(d)(1):

1. Marijuana within an FDA-approved product,
2. Marijuana cultivated and sold under qualifying state medical marijuana licenses, and
3. Covered marijuana extract and naturally derived delta-9-tetrahydrocannabinols tied to those products.

Cannabis industry observers have likely heard about the Trump administration’s broader effort to move marijuana generally from Schedule I to Schedule III under the Controlled Substances Act. That change, however, cannot be accomplished through a presidential executive order as discussed in our December 2025 client alert. Instead, it requires a DEA final order issued under 21 U.S.C. § 811(d)(1): the CSA provision directing the Attorney General to place a substance onto the schedule “he deems most appropriate” when such action is necessary to carry out U.S. treaty obligations. Those treaty requirements arise from the Single Convention on Narcotic Drugs, which obligates the United States to maintain comprehensive controls over cannabis, including production, licensing, quotas, recordkeeping, and import and export permitting.

Federal Recognition of State Medical Frameworks

The DEA has officially defined a state medical marijuana license as a license authorizing the holder “to manufacture, distribute, and/or dispense marijuana or products that contain marijuana for medical purposes”, reflecting its view that state medical systems are no longer peripheral to federal enforcement. The order says state programs have developed the infrastructure for diversion control, product safety, recordkeeping, and inspections, and that folding those systems into the federal registration framework is “the most effective and efficient means” of achieving CSA objectives for medical marijuana with the “least disruption for patients and existing state systems.”

For such licensees, the 2026 final order establishes a federal registration pathway under 21 C.F.R. § 1301.13(k) with an expedited six-month review process, under which a qualifying state license is “conclusive evidence” that the applicant is authorized to engage in regulated marijuana activities. The DEA says registrants will have to submit only the reports and records necessary to satisfy federal statutory and treaty obligations, and that it will accept “state-required reports, records, and forms to the maximum extent permissible.” The same goes, in several areas, for state-law labeling, packaging, disposal, and physical-security rules.

Three Registration Categories

The rule contemplates three types of federal registrations, subject to the limits of the underlying state license:

1. A registered manufacturer may cultivate, produce, process, package, label, and transfer marijuana to registered distributors or other manufacturers;
2. A registered distributor may receive marijuana from registered manufacturers and transfer it to registered dispensers or other distributors; and
3. A registered dispenser may dispense marijuana and marijuana products only to persons authorized by state law to possess them for medical purposes.

Notably, this leaves adult-use operators exactly where they were before, with the DEA stating plainly that “any form of marijuana other than in an FDA-approved drug product or marijuana subject to a state medical marijuana license remains a schedule I controlled substance.” As such, state-legal adult-use marijuana activities remain unequivocally illegal under federal law. Likewise, hemp and synthetically derived THC will fall outside the rescheduling order because they are excluded from the statutory definition of marijuana and the HHS evaluation that supported this order.

Ambiguity at the Edges of the Rule

For operators, the most exciting piece of the order is also where the ambiguity starts. The Acting Attorney General states that holders of state medical marijuana licenses “will no longer be subject to the deduction disallowance imposed by Section 280E”  while in the same breath, expressly stating that “[n]othing in this rule constitutes a determination regarding federal tax liability,” cautioning state licensees to “consult with tax counsel regarding the applicability of Section 280E to their specific circumstances.”  The US Treasury and IRS bluntly forecasts significant positive tax consequences for industry businesses, announcing forthcoming guidance in response to DEA changes.

Compounding the uncertainty even further, the DEA applies the ordinary statutory definition of “marijuana” to the cannabis plant and its covered derivatives but does not identify a separate species or chemically distinct category of “medical marijuana”. The same marijuana plant is treated differently depending only on the legal channel through which it’s cultivated, distributed, or dispensed. This framing leaves immediate room for dispute in states that don’t cleanly separate medical and adult-use licensure, and dual-use operators, where a single entity may hold multiple registrations.

DEA also adopted an unusual treaty-driven mechanism for registered manufacturers: the manufacturer must set a nominal price for its marijuana crops, DEA then purchases those crops at that price and sells them back to the manufacturer or a related entity, and the crops must remain in a facility to which DEA has access until the transaction is complete. By making DEA the purchaser and reseller of marijuana crops, the rule places a federal agency inside the transaction itself, even though marijuana remains federally prohibited outside the order’s narrow FDA-approved and state-licensed medical channels.

The Next Phase of Analysis

Dickinson Wright is continuing to evaluate the order’s consequences well beyond the headline Schedule III change, including its implications for banking and other capital access, the possibility of retrospective tax relief, private equity investment, M&A diligence, structuring, and risk allocation for cannabis businesses.

Stay tuned for additional client alerts as these issues develop.  Each state operator’s decisions of whether, when and how to register with the DEA should be based on its own facts and circumstances.  Please contact us if you want to discuss any of these issues.

Special thanks to Regulatory Compliance Strategist Jessica Kaiser for contributing to this article.